| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.410390506 |
| P698 | PubMed publication ID | 8619542 |
| P2093 | author name string | Myllylä VV | |
| Knip M | |||
| Isojärvi JI | |||
| Pakarinen AJ | |||
| Juntunen KT | |||
| Laatikainen TJ | |||
| P2860 | cites work | The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function | Q37544663 |
| Metabolic changes during treatment with valproate in humans: implication for untoward weight gain | Q47411038 | ||
| P433 | issue | 5 | |
| P921 | main subject | obesity | Q12174 |
| P304 | page(s) | 579-584 | |
| P577 | publication date | 1996-05-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Obesity and endocrine disorders in women taking valproate for epilepsy. | |
| P478 | volume | 39 |
| Q34299393 | 'Why getting fat, Doc?' Weight gain and psychotropic medications. |
| Q36194833 | A Large-Scale Study Indicates Increase in the Risk of Epilepsy in Patients With Different Risk Factors, Including Rheumatoid Arthritis |
| Q43140860 | A prospective audit of adjunctive zonisamide in an everyday clinical setting |
| Q44547038 | A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy |
| Q33961524 | Adverse effects of antiepileptic drugs |
| Q43744359 | Altered ovarian function and cardiovascular risk factors in valproate-treated women |
| Q35095179 | Anti-epileptic drugs in pregnancy: current safety and other issues |
| Q35960111 | Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study |
| Q38285318 | Antiepileptic drugs influences on body weight in people with epilepsy. |
| Q80397874 | Association of polycystic ovaries with the use of valproic Acid in jordanian epileptic patients |
| Q38244052 | Atherosclerosis in epilepsy: its causes and implications. |
| Q37552536 | Atherosclerotic risk among children taking antiepileptic drugs |
| Q36319420 | Best practice guidelines for the management of women with epilepsy |
| Q76378596 | Bipolar disorder in children and adolescents |
| Q35859819 | Bipolar disorders: special diagnostic and treatment considerations in women |
| Q46208501 | Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy |
| Q34458567 | Bodyweight gain and anticonvulsants: a comparative review |
| Q35014566 | Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review |
| Q51489539 | Characterization of insulin secretion in Valproate-treated patients with epilepsy. |
| Q33595627 | Child and adolescent bipolar disorder. |
| Q48134246 | Chronology and evolution of temporal lobe epilepsy and endocrine reproductive dysfunction in women: relationships to side of focus and catameniality |
| Q33982437 | Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia |
| Q41533636 | Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain |
| Q44663815 | Do women with epilepsy have increased frequency of menstrual disturbances? |
| Q41049740 | Does Valproic Acid Have Potential in the Treatment of Diabetes Mellitus? |
| Q90686930 | Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review |
| Q35889759 | Drug selection for the newly diagnosed patient: when is a new generation antiepileptic drug indicated? |
| Q35201012 | Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy |
| Q36058897 | Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy |
| Q44195061 | Effects of chronic valproate treatment on reproductive endocrine hormones in female and male Wistar rats |
| Q53559852 | Effects of epilepsy on women's reproductive health. |
| Q50331569 | Effects of valproate on sexual development |
| Q42163819 | Effects of valproate or lamotrigine monotherapy on the reproductive endocrine and insulin-related metabolic profile in Chinese adults with epilepsy: a prospective randomized study |
| Q51764458 | Endocrine effects of valproate in adolescent girls with epilepsy. |
| Q35090012 | Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. |
| Q37399586 | Epilepsy and hormones: a critical review |
| Q57119217 | Epilepsy in the northern Finland birth cohort 1966 with special reference to fertility |
| Q43708332 | Epilepsy needs revisited: a revised epilepsy needs document for the UK. |
| Q37642006 | Epilepsy, sex hormones and antiepileptic drugs in female patients. |
| Q37625064 | Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls |
| Q46784965 | Fatty liver in adults receiving antiepileptic medications: relationship to the metabolic risks |
| Q57543941 | Fertility and Birth Outcomes in Women With Epilepsy Seeking Pregnancy |
| Q35561522 | Gender differences in bipolar disorder |
| Q51891488 | Gender differences in major depressive disorder and bipolar disorder. |
| Q44663836 | Gonadal morphology and sex hormones in male and female Wistar rats after long-term lamotrigine treatment |
| Q46606260 | Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation |
| Q42602749 | Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy |
| Q43735961 | Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy |
| Q43873862 | Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate |
| Q92640386 | Increased risk of stroke and myocardial infarction in patients with epilepsy: A systematic review of population-based cohort studies |
| Q44043948 | Insulin resistance in epileptic girls who gain weight after therapy with valproic acid |
| Q46601959 | Insulin resistance in patients on valproic acid: relation to adiponectin |
| Q43799181 | Insulin-related metabolic changes during treatment with valproate in patients with epilepsy |
| Q48704040 | Interface between endocrinology and psychiatry in women with epilepsy: analysis of the relationship with comorbid pathology |
| Q33779880 | Is valproate pharmacotherapy associated with polycystic ovaries? |
| Q44402308 | Lamotrigine Versus Valproate Monotherapy—Associated Weight Change in Adolescents With Epilepsy: Results From a Post Hoc Analysis of a Randomized, Double-Blind Clinical Trial |
| Q30882064 | Lamotrigine in women with epilepsy. Review of present data |
| Q40771273 | Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study |
| Q34079108 | Management of epilepsy in adolescents and adults. |
| Q36284465 | Management options for bipolar disorder in children and adolescents |
| Q34977403 | Managing epilepsy in women of childbearing age. |
| Q35550766 | Medical comorbidities in the treatment of epilepsy |
| Q48575295 | Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy |
| Q35368221 | Metabolic dysfunction associated with adiponectin deficiency enhances kainic acid-induced seizure severity |
| Q98244606 | Metabolic syndrome and obstructive sleep apnea syndrome among patients with epilepsy on monotherapy |
| Q36400968 | Metabolic syndrome in bipolar disorders |
| Q41582248 | Minor head injury |
| Q33756716 | Monostars: an aid to choosing an antiepileptic drug as monotherapy |
| Q77783228 | Mood stabilizers and anticonvulsants |
| Q78235395 | New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment |
| Q46138227 | Nonalcoholic fatty liver disease during valproate therapy |
| Q44457521 | Nonketotic hyperosmolar syndrome from olanzapine, lithium, and valproic acid cotreatment |
| Q43632009 | Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents |
| Q35937900 | Obesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy |
| Q43856251 | Olanzapine-induced diabetic ketoacidosis |
| Q34301379 | On the association between valproate and polycystic ovary syndrome |
| Q34301384 | On the association between valproate and polycystic ovary syndrome: a response and an alternative view |
| Q36909255 | Pharmacotherapeutic strategies for pediatric bipolar disorder |
| Q34345051 | Polycystic ovarian syndrome in women with epilepsy: a review |
| Q24531421 | Polycystic ovaries and polycystic ovary syndrome in epilepsy: evidence for neurogonadal disease |
| Q35198091 | Polycystic ovary syndrome and epilepsy--a gynaecological perspective |
| Q35147061 | Polycystic ovary syndrome and epilepsy: a review of the evidence |
| Q74163690 | Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women |
| Q34881401 | Polycystic ovary syndrome in women using valproate: a review |
| Q38751494 | Post-epilepsy stroke: A review |
| Q61424521 | Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: Behavioral Risk Factor Surveillance System, 2002 |
| Q35987931 | Preventive treatment of migraine: effect on weight |
| Q81973646 | Preventive treatment of migraine: effect on weight |
| Q35255932 | Reduced levels of growth hormone, insulin-like growth factor-I and binding protein-3 in patients with shunted hydrocephalus |
| Q35540890 | Reproductive dysfunction in women with epilepsy |
| Q37301531 | Reproductive dysfunction in women with epilepsy: menstrual cycle abnormalities, fertility, and polycystic ovary syndrome |
| Q34745041 | Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management |
| Q79349474 | Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication |
| Q46494852 | Reproductive function and risk for PCOS in women treated for bipolar disorder |
| Q47259111 | Risk of excessive weight gain in epileptic children treated with valproate |
| Q36532168 | Role of androgens in epilepsy |
| Q41593966 | Serum Insulin and Leptin Levels in Children with Epilepsy on Valproate-associated Obesity |
| Q44004469 | Serum insulin and leptin levels in valproate-associated obesity |
| Q46897650 | Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate |
| Q33783545 | Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. |
| Q79867012 | Somatic treatment of bipolar disorder in children and adolescents |
| Q34240968 | Special issues in the treatment of paediatric bipolar disorder |
| Q37713560 | The Investigation of Insulin Resistance in Two Groups of Epileptic Patients Treated with Sodium Valproate and Carbamazepine |
| Q28485144 | The anti-epileptic drug valproic acid (VPA) inhibits steroidogenesis in bovine theca and granulosa cells in vitro |
| Q38106856 | The long-term safety of antiepileptic drugs |
| Q37432600 | The neuropathology of obesity: insights from human disease |
| Q34473848 | The pharmacologic treatment of the early phase of first-episode psychosis in youths |
| Q28068847 | The relationship between epilepsy and sexual dysfunction: a review of the literature |
| Q46980079 | The use of lamotrigine in female patients |
| Q43698020 | Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy |
| Q43694296 | Thyroid hormones in epileptic children receiving carbamazepine and valproic acid |
| Q39094490 | Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview |
| Q43923413 | Topiramate in migraine prevention: a double-blind, placebo-controlled study |
| Q57086621 | Tratamento de epilepsia: consenso dos especialistas brasileiros |
| Q34254779 | Treatment issues for women with epilepsy |
| Q46652012 | Treatment of epilepsy in adults: expert opinion, 2005. |
| Q35216355 | Understanding the information needs of women with epilepsy at different lifestages: results of the 'Ideal World' survey |
| Q47182175 | Upstream genetic variant near INSIG2, influences response to carnitine supplementation in bipolar patients with valproate-induced weight gain |
| Q43665509 | Valproate and the polycystic ovarian syndrome: final thoughts |
| Q44071758 | Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro |
| Q73628831 | Valproate treatment and the risk of hyperandrogenism and polycystic ovaries |
| Q51537591 | Valproate, bipolar disorder and polycystic ovarian syndrome. |
| Q43546464 | Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats |
| Q92355592 | Valproate, sexual health, and men: A narrative review |
| Q44292651 | Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women? |
| Q44466164 | Valproic acid fails to induce polycystic ovary syndrome in female rats |
| Q44568823 | Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients |
| Q44406536 | Valproic acid-associated weight gain in older children and teens with epilepsy |
| Q47442417 | Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study. |
| Q46675935 | Weight change in monozygotic twins treated with valproate |
| Q43140659 | Weight gain and insulin resistance in children treated with valproate: the influence of time |
| Q47233621 | Weight gain associated with valproate in childhood |
| Q37794213 | Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications |
| Q37171035 | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. |
| Q47303997 | Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. |
| Q36287145 | Women and epilepsy. |
| Q33899374 | Women with epilepsy: can the treatment be worse than the disease? |
| Q36896245 | Women with epilepsy: hormonal issues from menarche through menopause. |
Search more.